Similar articles

• Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review.

  Zielonke N, Gini A, Jansen EEL, Anttila A, Segnan N, Ponti A, Veerus P, de Koning HJ, van Ravesteyn NT, Heijnsdijk EAM; EU-TOPIA consortium. Zielonke N, et al. Eur J Cancer. 2020 Mar;127:191-206. doi: 10.1016/j.ejca.2019.12.010. Epub 2020 Jan 10. Eur J Cancer. 2020. PMID: 31932175
• The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies.

  Moss SM, Nyström L, Jonsson H, Paci E, Lynge E, Njor S, Broeders M; Euroscreen Working Group. Moss SM, et al. J Med Screen. 2012;19 Suppl 1:26-32. doi: 10.1258/jms.2012.012079. J Med Screen. 2012. PMID: 22972808 Review.
• The potential of breast cancer screening in Europe.

  Zielonke N, Kregting LM, Heijnsdijk EAM, Veerus P, Heinävaara S, McKee M, de Kok IMCM, de Koning HJ, van Ravesteyn NT; EU-TOPIA collaborators. Zielonke N, et al. Int J Cancer. 2021 Jan 15;148(2):406-418. doi: 10.1002/ijc.33204. Epub 2020 Jul 30. Int J Cancer. 2021. PMID: 32683673 Free PMC article.
• Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies.

  Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E; Euroscreen Working Group. Njor S, et al. J Med Screen. 2012;19 Suppl 1:33-41. doi: 10.1258/jms.2012.012080. J Med Screen. 2012. PMID: 22972809 Review.
• Why is breast-cancer mortality declining?

  Jatoi I, Miller AB. Jatoi I, et al. Lancet Oncol. 2003 Apr;4(4):251-4. doi: 10.1016/s1470-2045(03)01037-4. Lancet Oncol. 2003. PMID: 12681269 Review.